Experience of treatment of lung cancer patients using paclitaxel and carboplatin.

Ahmad Aulia, S. A. Mariono, Karmel Lindow Tambunan, A. H. Reksodiputro, N. Soetandyo, R. Hukom, E. Suratman, A. M. Jayusman

Research output: Contribution to journalArticlepeer-review


Nineteen patients with stage III & IV nonsmall cell lung cancer were treated with a regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina Central General Hospital, Jakarta, Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in 1 patient. Fourteen patients were in stage IV, 4 had stage IIIB, and one had stage IIIA disease. The regimen contained paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml.min, given every 3 weeks. Those who underwent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (PR) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 17.5 months and 19 months after starting chemotherapy. The one-year survival rate was 58%, and median survival time was 14 months.

Original languageEnglish
Pages (from-to)454-460
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume27 Suppl 2
Publication statusPublished - 1 Jan 2000


  • Carboplatin
  • Chemotherapy
  • Nonsmall cell carcinoma
  • Paclitaxel


Dive into the research topics of 'Experience of treatment of lung cancer patients using paclitaxel and carboplatin.'. Together they form a unique fingerprint.

Cite this